文献速递神经肿瘤

PIK3CA突变脑膜瘤中的激素关联:对靶向治疗与临床试验设计的启示

The hormonal nexus in PIK3CA-mutated meningiomas: implications for targeted therapy and clinical trial design.
PubMed 文献 · J Neurooncol · 2025-05-20

本文为叙述性综述,聚焦激素治疗与PIK3CA突变通路在脑膜瘤中的交叉点。流行病学证据提示接受激素治疗的患者PIK3CA突变率更高,而当前脑膜瘤激素治疗试验集中于生长抑素受体靶向治疗和肽受体放射性核素治疗,未明确针对PIK3CA-激素信号轴。作者认为探索该轴可能为激素治疗药物重定位提供信息。

要点

  • 脑膜瘤中激素受体的存在已为人所知数十年。
  • 服用口服避孕药、孕激素或激素替代治疗者脑膜瘤患病率增加。
  • 接受激素治疗的患者PIK3CA突变率更高,但该轴尚未被明确靶向。

核心结论

  • 由于描述激素治疗与突变PIK3CA通路在脑膜瘤中交叉点的文献相对匮乏,作者开展了本叙述性综述。
  • 鉴于PIK3CA突变在乳腺癌和前列腺癌等其他激素敏感肿瘤中促进癌症进展的作用,探索该轴可能为包括激素治疗在内的药物重定位提供信息。

研究设计与样本

  • 叙述性综述,检索范围原文未报告。

主要发现

  • 脑膜瘤中激素受体的存在已为人所知数十年。
  • 近期证据显示服用口服避孕药、孕激素或激素替代治疗等特定类型激素治疗的患者脑膜瘤患病率增加。
  • 流行病学证据提示接受激素治疗的患者PIK3CA致癌基因突变率更高。
  • 当前脑膜瘤激素治疗临床试验集中于生长抑素受体靶向治疗和肽受体放射性核素治疗,PIK3CA-激素信号轴尚未被明确靶向。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The presence of hormonal receptors in meningiomas has been known for decades. More recently, evidence has shown increased prevalence of meningiomas in patients taking certain types of hormonal treatments, such as oral contraceptives, progestins or hormone replacement therapy. Epidemiological evidence suggests that patients undergoing hormonal therapy harbor higher mutational rates of the oncogene PIK3CA. Due to the relative paucity of literature describing the intersection of hormone therapy and mutated PIK3CA pathways in meningioma, we have conducted a narrative review on this topic. Similarly, the clinical trial landscape for hormonal therapies for meningioma currently focuses on somatostatin receptor-targeted therapies and peptide receptor radionucleotide therapy, and the PIK3CA-hormonal signaling axis has not been explicitly targeted. Given the role of PIK3CA mutations in promoting cancer progression in other hormone-sensitive tumors, such as breast and prostate cancer, exploring this axis could inform drug repurposing including hormonal therapy specifically for these tumors.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Abikenari M, Regev A, Himic V, et al. The hormonal nexus in PIK3CA-mutated meningiomas: implications for targeted therapy and clinical trial design. J Neurooncol. 2025. PMID: 40392516. doi:10.1007/s11060-025-05082-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。